Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% Compared to Placebo – – An Exploratory Analysis of CLEAR ...

Medifast, the health and wellness company known for its science-backed, coach-guided lifestyle system, continues to lead the charge in addressing the growing health crisis of metabolic dysfunction by ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for ...

New information to be presented on the study design and methodology of Purespring’s Phase I/II trial of PS-002, an AAV-based ...

Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and ...

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy ® (epinephrine ...

CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, ...

MRT-8102 is a selective, potent, and durable NEK7 degrader. Activation of the NLRP3 inflammasome critically depends on NEK7. Administration of MRT-8102 led to inhibition of NLRP3 inflammasome in vitro ...

SYRACUSE, NY / ACCESS Newswire / November 11, 2025 / Repair Biotechnologies, Inc. ( today announced the recent presentation of preclinical data at American Heart Association's (AHA) Scientific ...

Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines NANTES, France, ...

SYRACUSE, NY / ACCESS Newswire / November 11, 2025 / Repair Biotechnologies, Inc. ( today announced the recent presentation of preclinical data at American Heart ...